Hypothesis

The pathogenic load of mitochondrial DNA (mtDNA) mutations does not linearly translate into aging phenotypes; instead, nuclear‑encoded regulators of mitophagy set a threshold that determines whether accumulated mtDNA damage triggers cellular senescence or is tolerated.

Mechanistic rationale

1. mtDNA heteroplasmy burden rises with age due to polymerase γ errors [2].
2. Mitophagy flux is controlled by nuclear genes such as PINK1, Parkin, and BNIP3, whose expression is modulated by epigenetic and signaling pathways (e.g., AMPK, mTOR) [3].
3. When mitophagy capacity exceeds the rate of mtDNA damage, damaged mitochondria are removed, limiting ROS spread and apoptosis signaling [4].
4. If nuclear mitophagy machinery is downregulated—by age‑related histone deacetylase activity or nutrient‑sensing pathways—heteroplasmic mtDNA mutations persist, bioenergetic decline ensues, and epigenetic clocks accelerate [5].

Thus, the nuclear genome acts as a gatekeeper: interventions that boost mitophagy (e.g., NAD+ boosters, urolithin A) should uncouple mtDNA mutation load from aging phenotypes, whereas nuclear‑encoded mitophagy loss should exacerbate aging even with low mtDNA mutation burden.

Testable predictions

• Prediction 1: In mtDNA mutator mice, pharmacological activation of PINK1‑Parkin mitophagy will delay onset of alopecia, blindness, and muscular atrophy without reducing mtDNA mutation frequency [6].
• Prediction 2: Human fibroblasts engineered to overexpress BNIP3 will show lower senescence‑associated β‑galactosidase activity despite high heteroplasmic mtDNA deletions, measured by unchanged epigenetic age (Horvath clock) [7].
• Prediction 3: CRISPR‑mediated knock‑down of PARKIN in young, low‑heteroplasmy iPSCs will prematurely increase epigenetic age and metabolic shift, mimicking aged phenotypes [8].

Falsifiability

If enhancing mitophagy fails to improve functional outcomes in mtDNA mutator models, or if suppressing mitophagy does not accelerate aging phenotypes in low‑mutation contexts, the hypothesis that nuclear‑encoded mitophagy gates mtDNA‑driven aging is falsified.

Broader implication

This reframes the debate: the nuclear genome is not a passive passenger but an active regulator that can either mask or amplify mitochondrial damage. Longevity strategies should therefore target the nuclear‑mitochondrial interface, not just mtDNA repair.